Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression

Inclusion Criteria: * Age ≥ 18 years. * Histologically or cytologically metastatic NSCLC (UICC/AJCC TNM Staging System, 9th Edition, Stage Ⅳ). * At least one measurable target tumor lesion as accessed by RECIST v1.1 criteria. * Documented ROS1 gene fusion identified by an approved molecular testing method (FISH, RT-PCR, or NGS). * Progressed following entrectinib treatment, regardless of prior exposure to chemotherapy, antiangiogenic multikinase inhibitors, or immunotherapy. * Considered by the investigator to be candidates for Taletrectinib treatment ; OR Patients with ≤6 months of prior Taletrectinib exposure enrolled retrospectively. (Note: For retrospective patients deceased before enrollment, waiver of informed consent is required. Patients who initiated and discontinued treatment within 6 months prior to signing informed consent are eligible). * Signed Informed Consent. Exclusion Criteria: * Patients with driver gene mutations/alterations that have approved targeted therapies , including but not limited to EGFR, ALK, RET, etc. * Currently participating in other interventional clinical trials or having received investigational drug treatment within 4 weeks prior to enrollment . * Pregnancy or breastfeeding. * Patients with uncontrolled co-morbidities who are assessed by the investigator not to receive targeted therapy. * Other conditions that are assessed by the investigator to be unsuitable for enrollment in this study.